[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intracranial-hemorrhage-spontaneous\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intracranial-hemorrhage-spontaneous":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100617257","safety-and-effectiveness-of-catheter-ablation-for-atrial-fibrillation-with-intracranial-hemorrhage-safer-af-100617257",false,"NCT07316270","SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF)","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Between 14 Days and 12 Months After Spontaneous Intracranial Hemorrhage (intraparenchymal or intraventricular hemorrhage, and subdural hematoma)\n3. Able to Access Intracranial Hemorrhage Imaging Data\n4. ECG indicating the presence of atrial fibrillation\n5. CHA₂DS₂-VA Score ≥ 2\n6. Willing to undergo randomization and able to complete follow-up as required\n\nExclusion Criteria:\n\n1. Atrial fibrillation secondary to clearly reversible causes (e.g., hyperthyroidism, hypokalemia, etc.)\n2. Fully dependent (modified Rankin Scale \\[mRS\\] score \\> 4)\n3. Uncontrolled hypertension (systolic blood pressure \\> 160 mmHg)\n4. Presence of uncontrolled active bleeding\n5. Presence of active infection requiring antibiotic treatment\n6. End-stage renal failure or receiving dialysis treatment\n7. Presence of liver failure\n8. Untreated coronary artery disease with indication for revascularization\n9. Presence of intracardiac masses, thrombi, etc., as evaluated by transthoracic echocardiography or transesophageal echocardiography\n10. Expected life expectancy \\\u003C 1 year (e.g., advanced malignant tumors, etc.)\n11. Pregnant, lactating, or women planning to become pregnant\n12. Presence of psychological or psychiatric disorders that prevent understanding or cooperation with the study\n13. Other conditions deemed unsuitable for participation in the study by the investigators","ALL","18 Years",{"count":18,"type":19},646,"ESTIMATED","INTERVENTIONAL",[22],"NA","SAFER-AF is an investigator-initiated, multicenter, open-label, parallel-group trial comparing catheter ablation versus usual care in patients with atrial fibrillation and intracranial hemorrhage.",[25,26],"AF - Atrial Fibrillation","Intracranial Hemorrhage, Spontaneous","RECRUITING","2026-08-05",{"date":30,"type":31},"2026-08-07","ACTUAL",{"date":33,"type":31},"2026-05-06",{"date":35,"type":19},"2030-01",{"name":37,"class":38},"Beijing Anzhen Hospital","OTHER",7,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":50,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100608723","rainbow-ich-trial-of-ai-guided-minimally-invasive-neurosurgery-for-ich-100608723","NCT07205263","RAINBOW-ICH Trial of AI Guided Minimally Invasive Neurosurgery for ICH","A Multicenter, Randomized, Controlled, Umbrella Trial for Minimally Invasive Neurosurgery With Al-assisted Robotic Guidance for Hemorrhagic Stroke (RAINBOW-ICH)","RAINBOW-ICH","Umbrella Trial Inclusion Criteria:\n\n1. Age ≥18 years；\n2. Clinical diagnosis of spontaneous hemorrhagic stroke；\n\nUmbrella Trial Exclusion Criteria:\n\n1\\. Radiologically diagnosed cerebrovascular abnormalities, as well as ischemic infarction converting to intracerebral hemorrhage, or recent (within 1 year) recurrence of intracerebral hemorrhage；\n\nEach substudy will specify additional inclusion and exclusion criteria in the respective Substudy-specific Registration. Patients who fulfill the overall umbrella trial criteria will be assessed for enrollment into each substudy.",{"count":49,"type":19},1000,[22],"Intracerebral hemorrhage (ICH) is one of the most devastating forms of stroke, with high rates of death and disability worldwide. Despite advances in medical and surgical care, effective therapeutic options remain limited. To address this gap, the RAINBOW-ICH trial has been designed as a nationwide, multicenter, randomized umbrella trial evaluating the efficacy and safety of AI-assisted, robotic-guided minimally invasive neurosurgery compared with conventional strategies across major ICH subtypes.\n\nUnder a single master protocol, RAINBOW-ICH incorporates multiple parallel randomized controlled substudies, each targeting a distinct ICH population-large basal ganglia hemorrhage, moderate basal ganglia hemorrhage, intraventricular hemorrhage, and brainstem hemorrhage. This umbrella design allows efficient use of resources while generating high-quality evidence tailored to the specific needs of different ICH subgroups, thereby supporting a more patient-centered approach to care.",[53,54,55,26],"Basal Ganglia Hemorrhage","Intraventricular Hemorrhage","Brainstem Stroke",[57,58,55,59,53,60],"Umbrella Trial","Intraventricular hemorrhage","Robotic-guided","Minimally invasive surgery","2026-01-06",{"date":63,"type":31},"2026-01-08",{"date":65,"type":31},"2025-09-30",{"date":67,"type":19},"2027-12",{"name":69,"class":38},"Second Affiliated Hospital, School of Medicine, Zhejiang University",1]